Heart safety check for promising sickle cell drug
NCT ID NCT07023029
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This study checks whether etavopivat, a new medicine for sickle cell disease and thalassemia, changes the heart's electrical activity. It involves 33 healthy adults who receive different doses of the drug, a placebo, or an approved heart medication. The goal is to ensure the drug is safe for the heart before moving to larger patient studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
PAREXEL Intl - EPCU-Baltimore
Baltimore, Maryland, 21225, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Etavopivat
What this could lead to
If successful, this study will confirm that etavopivat is safe for the heart, supporting its further testing as a potential treatment for sickle cell disease and thalassemia.
What could go wrong
This is an early phase 1 study in only 33 healthy people, not patients. It only looks at heart safety, not whether the drug works for the disease. Results may not predict effects in patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.